Dr. E. David Crawford spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “Update of Androgen Deprivation Therapy.”
Keywords: prostate cancer, cardiovascular side effects, androgen deprivation therapy (ADT)
How to cite: Crawford, E. David. “Update of Androgen Deprivation Therapy” Grand Rounds in Urology. August 5, 2015. Accessed Nov 2024. https://dev.grandroundsinurology.com/prostate-cancer-e-david-crawford-update-of-androgen-deprivation-therapy/.
References
Arcadi JA. Rapid drop in serum testosterone after bilateral subcapsular orchiectomy. J Surg Oncol. 1992 Jan;49(1):35-8.
http://www.ncbi.nlm.nih.gov/pubmed/1548879
Ben-Josef E, Yang SY, Ji TH, et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999 Mar;161(3):970-6.
http://www.ncbi.nlm.nih.gov/pubmed/10022736
Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002 Apr;301(1):95-102.
http://www.ncbi.nlm.nih.gov/pubmed/11907162
Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res. 1992 Oct;1(5):323-9.
http://www.ncbi.nlm.nih.gov/pubmed/1299464
Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24.
http://www.ncbi.nlm.nih.gov/pubmed/2503724
Crawford ED, Rove KO. Incomplete testosterone suppression in prostate cancer. N Engl J Med. 2010 Nov 11;363(20):1976.
http://www.ncbi.nlm.nih.gov/pubmed/21067409
Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep;186(3):889-97.
http://www.ncbi.nlm.nih.gov/pubmed/21788033
Dansky HM, Charlton SA, Harper MM, et al. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4642-6.
http://www.ncbi.nlm.nih.gov/pubmed/9114044
Epstein MM, Edgren G, Rider JR, et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012 Sep 5;104(17):1335-42.
http://www.ncbi.nlm.nih.gov/pubmed/22835388
Garde S, Sheth A, Porter AT, et al. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate. 1993;22(3):225-33.
http://www.ncbi.nlm.nih.gov/pubmed/8488155
Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Actas Urol Esp. 2011 Oct;35(9):501-14.
http://www.ncbi.nlm.nih.gov/pubmed/21757259
Kaisary AV, Tyrrell CJ, Peeling WB, et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502-8.
http://www.ncbi.nlm.nih.gov/pubmed/1828183
Ketchandji M, Kuo YF, Shahinian VB, et al. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009 Jan;57(1):24-30.
http://www.ncbi.nlm.nih.gov/pubmed/19054189
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8.
http://www.ncbi.nlm.nih.gov/pubmed/19035858
Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004 Apr;25(2):235-75.
http://www.ncbi.nlm.nih.gov/pubmed/15082521
Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007 Oct;178(4 Pt 1):1290-5.
http://www.ncbi.nlm.nih.gov/pubmed/17698136
Morote J, Esquena S, Abascal JM, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int. 2006;77(2):135-8.
http://www.ncbi.nlm.nih.gov/pubmed/16888418
Nakabayashi M, Werner L, Oh WK, et al. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec;9(2):95-103.
http://www.ncbi.nlm.nih.gov/pubmed/21958520
Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000 Dec 20;56(6):1021-4.
http://www.ncbi.nlm.nih.gov/pubmed/11113751
Røhl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol. 1992;26(1):11-4.
http://www.ncbi.nlm.nih.gov/pubmed/1631501
Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 4;132(7):566-77.
http://www.ncbi.nlm.nih.gov/pubmed/10744594
Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005 Jul 13;294(2):238-44.
http://www.ncbi.nlm.nih.gov/pubmed/16014598
Sweeney CJ. ECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease inprostate cancer. Clin Adv Hematol Oncol. 2006 Aug;4(8):588-90.
http://www.ncbi.nlm.nih.gov/pubmed/17111557
Thompson IM. Flare Associated with LHRH-Agonist Therapy. Rev Urol. 2001;3 Suppl 3:S10-4.
http://www.ncbi.nlm.nih.gov/pubmed/16986003
Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995 Aug;46(2):220-6.
http://www.ncbi.nlm.nih.gov/pubmed/7624991
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
He is currently a Professor of Urology at the University of California, San Diego, and emeritus distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians.
In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC.
Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.
Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.
